Stephen L. Chan

Chinese University of Hong Kong — Hong Kong

Medicine · Health Sciences

84h-index36.4kcitations730works11.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(279), Liver Disease Diagnosis and Treatment(107), Cancer Immunotherapy and Biomarkers(97), Pancreatic and Hepatic Oncology Research(97), Cholangiocarcinoma and Gallbladder Cancer Studies(61)

Publications723 total

Safety outcomes with tremelimumab (T) rechallenge in the phase 3 HIMALAYA study of T plus durvalumab (D) in unresectable hepatocellular carcinoma.
Journal of Clinical Oncology·2026
Impact of liver function on survival outcomes in patients (pts) treated with first-line atezolizumab-bevacizumab (Atezo-Bev) for unresectable hepatocellular carcinoma (uHCC): Asia-Pacific multicenter retrospective analysis.
Journal of Clinical Oncology·2026
Sequential transarterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy using single tremelimumab regular interval durvalumab in locally advanced, unresectable HCC (START-FIT using STRIDE): A single-arm, phase II, multi-centre study.
Journal of Clinical Oncology·2026· 1 cited
ARTEMIDE-HCC01: A phase 3, randomized, open-label, sponsor-blinded, multicentre, global study of rilvegostomig in combination with bevacizumab with or without tremelimumab as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC).
Journal of Clinical Oncology·2026
Survival outcomes in patients (pts) with Child-Pugh class B (CP-B) liver function at progression after first-line atezolizumab-bevacizumab (Atezo-Bev) for unresectable hepatocellular carcinoma (uHCC): Asia-Pacific multicenter retrospective analysis.
Journal of Clinical Oncology·2026
Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study.
Journal of Clinical Oncology·2026· 2 cited
What’s next after the 2026 BCLC update?
Journal of Hepatology·2025
Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis
Liver Cancer·2025Open Access
Clinical Implications of Upregulated RSAD2 Gene Expression in Hepatocellular Carcinoma
Diseases·2025Open Access
Specific indicators of unsuitability for transarterial chemoembolisation in patients with intermediate-stage hepatocellular carcinoma according to thresholds of tumour burden and liver function as judged by survival benefit over sorafenib
Hong Kong Medical Journal·2025Open Access
Radiation-induced Lymphopenia is Associated with Survival in Patients with Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy
JHEP Reports·2025Open Access
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
The Lancet Oncology·2025· 3 cited
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers
Liver International·2025· 3 citedOpen Access
Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma
Nature Communications·2025· 1 citedOpen Access
Ethiodized Oil–based Transarterial Chemoembolization for Hepatocellular Carcinoma: Randomized Clinical Trial of Anhydrous Cisplatin Suspension versus Cisplatin Emulsion
Radiology·2025
Letter: Antiviral Prophylaxis Mitigates <scp>HBV</scp> Reactivation Risk During Cancer Immunotherapy: Unresolved Challenges and Future Directions—Authors' Reply
Alimentary Pharmacology & Therapeutics·2025Open Access
Clinical management of liver cancer patients with immune checkpoint inhibitors treatment
Hepatic Oncology·2025Open Access
Establishing core outcomes and minimal clinically important differences for childhood steroid sensitive nephrotic syndrome clinical trials: results from a Delphi consensus process
Pediatric Nephrology·2025
Editorial: Immune Checkpoint Inhibitors and <scp>HBV</scp> Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
Alimentary Pharmacology & Therapeutics·2025Open Access
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab
European Journal of Cancer·2025
page 1 of 37Next →

Frequent Co-authors

Masatoshi Kudo(16), Paul B.S. Lai(13), Frankie Mo(11), Winnie Yeo(10), Ann‐Lii Cheng(10), Anthony T.�C. Chan(10), Anthony W.H. Chan(10), Bruno Sangro(9), John Wong(9), Arndt Vogel(8), Mohamed Bouattour(8), В. В. Бредер(8), Rossa W. K. Chiu(8), Brigette Ma(8), Ka‐Fai To(8), Philip J. Johnson(7), Robin Kate Kelley(7), Lorenza Rimassa(7), Peiyong Jiang(7), K.C. Allen Chan(7)